Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance

International Journal of Cancer

Volumn 100, Issue 1, 2002, Pages 22-29

  Van Hattum, Annemarie H ^a   Schlüper, Hennie M M ^a   Hausheer, Frederick H ^b   Pinedo, Herbert M ^a   Boven, Epie ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BioNumerik Pharmaceuticals Inc   (United States)

^c NONE   (Netherlands)

Author keywords

BCRP; BNP1350; Human ovarian cancer xenografts; Karenitecin; Multidrug resistance; Topoisomerase I inhibitors

Indexed keywords

7 [(2 TRIMETHYLSILYL)ETHYL]CAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; EXATECAN; FLUOROURACIL; KARENITECIN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL DIVISION; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036643756     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10434     Document Type: Article

References (37)

1. Plant antitumor agents. I. The isolation and structure of Camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. Topoisomerase I inhibitors: Selectivity and cellular resistance
3. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy
4. Topotecan, an active new antineoplastic agent: Review and current status
5. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
6. Karenitecins (Part II): A novel class of orally active highly lipophilic topoisomerase I inhibitors
7. Karenitecins: Further developments with BNP1350, a novel, highly lipophilic, lactone stable camptothecin
8. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
9. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
10. Relationship between P-glycoprotein, multidrug resistance-associated protein, and cellular accumulation of topoisomerase I inhibitors
11. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter
12. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
13. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918
14. Preclinical activity of DX-8951f (exatecan mesylate) and induction of Breast Cancer Resistance Protein (BCRP) as a mechanism of resistance
15. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
16. Reversal of adriamycin resistance by verapamil in human ovarian cancer
17. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice
18. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors
19. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei
20. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
21. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
22. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance
23. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies
24. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
25. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
26. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
27. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system
28. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line
29. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance
30. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin
31. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
32. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6
33. Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype
34. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line
35. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
36. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
37. Oral topotecan: Bioavailablity and effect of food co-administration